Comparative Pharmacology
Head-to-head clinical analysis: AZOPT versus DICHLORPHENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOPT versus DICHLORPHENAMIDE.
AZOPT vs DICHLORPHENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
25-50 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor